An Introduction to Glaucoma
Numerous updates in the glaucoma treatment landscape have had a big impact on patient outcomes. The introduction of minimally invasive glaucoma surgeries (MIGS) and the approval of new drugs with new mechanisms of action, for the first time in decades, have transformed the landscape. Ongoing research into new drug delivery systems is likely to provide more effective and convenient treatments in the future.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Once-daily Preservative-free Topical Anti-glaucomatous Monotherapy – A Better Approach?
European Ophthalmic Review. 2020;14(1):21–5 DOI: https://doi.org/10.17925/EOR.2020.14.1.21
Glaucoma causes an optic neuropathy and is one of the leading causes of blindness globally.1 Pathologically, patients with glaucoma typically develop irreversible characteristic field defects due to loss of retinal ganglion cells and subsequent characteristic optic nerve-head damage. The main risk factor for development of glaucoma is intraocular pressure (IOP), reduction of which is targeted by […]
Clear Lens Extraction in Primary Angle-Closure Disease—Pros and Cons
US Ophthalmic Review. 2020;13(1):23–9 DOI: https://doi.org/10.17925/USOR.2020.13.1.23
Recently, new surgical modalities for management of primary angle-closure disease (PACD) have been proposed; the most controversial of which being clear lens extraction (CLE). The Effectiveness in Angle-closure Glaucoma of Lens Extraction (EAGLE) and other studies recommend CLE as the primary procedure of choice to manage eyes with PACD.1–5 However, the rationale for CLE without resorting […]
Innovations in the Surgical Management of Glaucoma
European Ophthalmic Review 2020;14(Suppl. 1):2–7
It is an exciting time in the field of surgical management of glaucoma. The introduction of new devices and procedures that can lower intraocular pressure (IOP) in a safer and less invasive fashion than traditional glaucoma surgery has made it possible to consider a more proactive approach to surgical glaucoma management. This update on innovations […]
A Topical Preservative-free Fixed-dose Combination Remedy in Patients with Glaucoma with Insufficient Response to Monotherapy – The VISIONARY Study
European Ophthalmic Review. 2019;13(2): Epub ahead of print
Glaucoma is a progressive optic neuropathy and is the leading cause of irreversible blindness worldwide.1 Despite substantial improvements in technology, therapies, and our understanding of the disease, people continue to go blind from glaucoma due to inadequate disease control.1 Medical treatment is initiated with a single topical hypotensive agent, as recommended by the European Glaucoma Society.2 However, monotherapy […]
Surgery for Normal Pressure Glaucoma—Is There a Role for Minimally Invasive Glaucoma Surgery Before Filtering Surgery?
US Ophthalmic Review, 2019;12(2):57–8
Normal tension glaucoma (NTG), also known as normal pressure or low tension glaucoma, is characterized by damage to the optic nerve without raised intraocular pressure (IOP).1,2 For many years ophthalmologists have found the diagnosis of NTG challenging, but following the Collaborative Normal Tension Glaucoma Study, it is generally accepted that IOP reduction can prevent or slow […]
Allocating Resources for Glaucoma Care—A Review
US Ophthalmic Review, 2019;12(2):78-84
The cost of glaucoma care is high1–3 and involves both the direct cost of eye consultations/examinations, investigations, medications or surgical interventions, as well as the indirect costs of loss of daily revenue during clinic visits, transport costs of self and care giver and the unquantifiable cost of psychological stress and blindness. These costs are recurrent […]
Minimally Invasive Glaucoma Surgery with a New Ab-externo Subconjunctival Bypass – Current Status and Review of Literature
European Ophthalmic Review. 2019;13(1):27–30 DOI: https://doi.org/10.17925/EO R.2019.13.1.27
The PRESERFLO™MicroShunt (Santen, Osaka, Japan), formerly known as the InnFocus MicroShunt (Santen, Osaka, Japan), is a minimally invasive glaucoma drainage device, intended to shunt aqueous humour from the anterior chamber (AC) of the eye to a filtration bleb, formed under the conjunctiva and Tenon’s capsule. The device was initially designed for use in patients with […]
From Eye Drops to Surgical Intervention – When and What to do
European Ophthalmic Review. 2019;13(Suppl 1):Epub ahead of print
Medical treatment – keeping 24-hour intraocular pressure control while maintaining conjunctival integrity Intraocular pressure (IOP) is the main risk factor for the development and progression of glaucoma.1,2 The Ocular Hypertension Treatment Study (OHTS), Collaborative Normal Tension Glaucoma Study (CNTGS), United Kingdom Glaucoma Treatment Study (UKGTS) and Early Manifest Glaucoma Trial (EMGT) all demonstrated longer times […]
Anthony Khawaja, SOE 2019 – Recent developments in glaucoma
Anthony Khawaja (Moorfields, UK) talks about the unmet needs in glaucoma including late detection due to insufficient screening methods along with limited understanding of how well a patient will respond to treatment. Research into genetic factors is an exciting area of current and future research. 1. What have been the most significant recent developments in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!